For US Audiences Only

FOR US HEALTHCARE PROFESSIONALS

Contact a Recordati Rare Diseases Representative

For US Audiences Only

STARTING YOUR PATIENTS ON CYSTADROPS

CYSTADROPS is dispensed exclusively through the specialty pharmacy Anovo.

TO START TREATMENT:

Download and fill out a CYSTADROPS treatment form that serves as a prescription.
Fax the form to 1-855-813-2039.
Anovo representatives will work with your office to provide benefit verification and prior authorization support, if needed.
Anovo will ship CYSTADROPS to the patient’s home and provide follow-up calls to answer questions and promote adherence.

For e-prescribing, select "Anovo #5"

QUESTIONS?

CALL 866-925-6212

FINANCIAL RESOURCES FOR YOUR PATIENTS

Recordati Rare Diseases, the distributor of CYSTADROPS, is committed to reducing financial barriers for your patients.

THE FOLLOWING PROGRAMS ARE AVAILABLE TO ASSIST YOUR PATIENTS:

Copay Assistance Program

Assists eligible patients with insurance copayments or co-insurance for CYSTADROPS.

Patient Assistance Program

Assists qualified uninsured or underinsured patients to gain access to CYSTADROPS.

CYSTADROPS RESOURCES FOR YOUR PATIENTS

CYSTADROPS Dropper Assembly & Administration Guide

CONTACT AN RRD REPRESENTATIVE

To learn more about CYSTADROPS, schedule an appointment with a Recordati Rare Diseases representative.

Contact a Recordati Rare Diseases Representative

Clinical Data & Safety

REVIEW THE RESULTS

Dosing & Administration

LEARN MORE

Indications and Usage

CYSTADROPS (cysteamine ophthalmic solution) 0.37% is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis.

Important Safety Information

To minimize the risk of contamination, do not touch the dropper tip to any surface. Keep bottle tightly closed when not in use.
Benign intracranial hypertension (or pseudotumor cerebri) associated with oral cysteamine or ophthalmic use of cysteamine (with concurrent oral cysteamine) has been reported, which has resolved with diuretic therapy.
Contains benzalkonium chloride. Contact with soft contact lenses should be avoided. Remove contact lenses prior to application. Lenses may be reinserted 15 minutes following administration.
The most common adverse reactions (≥ 10%) are eye pain, vision blurred, eye irritation, ocular hyperaemia, instillation site discomfort, eye pruritus, lacrimation increased, and ocular deposits.
To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344, or FDA at 1‑800-FDA-1088 or www.fda.gov/medwatch.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

+ SEE MORE

Important Safety Information

To minimize the risk of contamination, do not touch the dropper tip to any surface. Keep bottle tightly closed when not in use.